• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Penthrox methoxyflurane inhaler approved in Canada and several European countries

Penthrox, a methoxyflurane inhaler, has been approved in Canada for short-term relief of moderate to severe pain resulting from trauma or medical procedures, Medical Developments International (MDI) said. The company announced in June 2017 that its marketing authorization application had been accepted for review by Health Canada.

Purdue Pharma, acquired Canadian rights to Penthrox in 2016. MDI CEO John Sharman commented, ” We’re proud to have a partner, like Purdue, with a long and successful legacy in treating pain, now making Penthrox available to Canadian patients who are suffering from moderate to severe acute pain due to trauma or undergoing interventional medical procedures.”

Mr Sharman continued, “Under the terms of the exclusive agreement between the companies, Purdue Pharma (Canada) has the exclusive right to register, market, promote, distribute and sell Penthrox in Canada. MDI will retain clinical development activities, as well as the manufacture and supply of Penthrox to Purdue Pharma (Canada).”

Purdue Pharma Canada VP, R&D, Tom Koutsavlis said, “From my experience, a non-invasive, fast-acting, treatment option that does not require opioid-associated monitoring, like Penthrox, is necessary. Penthrox has the added benefit of being a lightweight, portable, handheld inhaler which is also patient-controlled. Not only has it been shown to be safe and effective, it can also help simplify trauma treatments for both patients and their caregivers.”

In the past few weeks, Penthrox has also received marketing authorization in Germany, Sweden, Norway, Poland, and Croatia.

Read the MDI press release on the Canadian approval.

Read the MDI press release on the German approval.

Read the MDI press release on the approvals in other European countries.

Share

published on April 11, 2018

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews